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Controlling blood lipids is a major public health challenge of our time. The pleiotropic 
hormone-like polypeptide fibroblast growth factor 21 (FGF21) was recently recognized 
as a potent modulator of lipid and glucose metabolism and a promising treatment strategy 
for obesity related metabolic disorders, including dyslipidemia. A cost effective and 
practical alternative to the administration of recombinant FGF21 is to stimulate 
endogenous FGF21 production through diet. Our research identified (R)--lipoic acid 
(LA), a naturally occurring enzyme cofactor and dietary molecule found in green leafy 
vegetable and red meat, as an inducer of FGF21 expression. LA stimulated FGF21 
production, demonstrated by a 3-fold increase in circulating FGF21, in the obese animal 
by upregulating hepatic Fgf21 expression. Concomitantly, feeding LA to dyslipidemic 
obese rats corrected high blood triacylglycerol levels and lowered abdominal adiposity by 
stimulating liver gene expression of peroxisome proliferator-activated receptor  
(PPAR target genes involved in lipid disposal and conjointly decreasing de novo lipid 
synthesis as a two-sided complementary mechanism to mitigate lipid burden. Since the 
 metabolic effects of LA mimic those of FGF21, we posit that FGF21 mediates the 
beneficial phenotype evoked by LA and sought to determine how LA and its reduced 
form, (R)--dihydrolipoic acid (DHLA), induce the Fgf21 promoter. To that end, we 
employed HepG2 hepatocellular carcinoma cells under fed and starved states and in the 
presence of LA and DHLA. Serum withdrawal markedly induced FGF21 mRNA 
abundance from 24 to 48 hours after serum removal. Both LA and DHLA induced 
FGF21 mRNA levels at 36 hours after serum removal when compared to vehicle control. 
To further determine the regulatory mechanism of FGF21 transcription, we have begun 
to develop the FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) assay 
coupled to qPCR to isolate and identify active regulatory promoter regions. We designed 
and validated a collection of primers specific for human FGF21 promoter that will allow 
the functional mapping of a 4,573-bp 5’ UTR region. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
Controlling blood lipids is a major public health challenge of our time, when over 
100 million Americans are overweight or obese. The National Cholesterol Education 
Program considers hypertriglyceridemia (i.e. fasting blood triglyceride (TG) levels 150 
mg/dl or 1.5 mM) to be an independent risk factor for coronary heart disease [1]. 
Lowering blood TG translates into substantial cardiovascular benefits. For instance, a 
29% reduction in TG is associated with a 22% reduction in coronary heart disease 
mortality [2]. Hypertriglyceridemia is also a major risk factor for liver disease and type-2 
diabetes [3]. Despite significant advances in treatment ~65 million Americans have 
hypertriglyceridemia. 
Conventional therapy for hypertriglyceridemia includes dietary weight loss and 
exercise, dietary supplementation with fish oil or niacin, and drug intervention, which 
may include fibrates or combined therapy with statins when LDL-cholesterol is elevated 
(Table 1.1). As the country is facing an obesity epidemic, the likelihood of controlling 
hypertriglyceridemia by weight loss – on an epidemiological scale – is proving elusive at 
best. Although some improvement is noted with drug therapies, serious associated side 
effects remain a concern. Thus, clinicians must administer lipid-lowering drugs carefully, 
especially in patients with renal and hepatic dysfunction, and in the elderly. This grim 
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picture means that an ever-growing number of hypertriglyceridemic patients will not be 
adequately treated for their lipid disorder and remain at elevated risk for cardiovascular 
disease, liver disease, and type-2 diabetes. There is, therefore, a critical need to identify 
therapeutic agents that would lessen hypertriglyceridemia and also be safe and relatively 
inexpensive. 
 
Fibroblast growth factor 21 (FGF21) 
The endocrine hormone fibroblast growth factor 21 (FGF21) is a pleiotropic 
hormone-like protein that encoded by human FGF21 gene. FGF21 was classified as a 
fibroblast growth factor based on its structure, since it contains a typical structure domain 
of FGF and shares 10–30% sequence identity with other FGFs, mostly FGF19 [4]. It has 
long been detected as a powerful modulator of lipid and glucose metabolism and a 
promising treatment strategy for obesity related metabolic disorders [5,6,7,8]. FGF21 is 
expressed in liver, pancreas, adipose and muscle tissue [9,10]. FGF21 functions through 
binding to cell-surface FGF receptor (FGFR)/-Klotho complex in target tissues [11,12] 
(Fig. 1.1. & 1.2.). Induction of liver FGF21 expression is required for normal activation 
of lipid oxidation and TG catabolism [5,13]. Conversely, genetic deletion of FGF21 
results in fatty liver and hypertriglyceridemia [13]. The administration of FGF21 to obese 
rats and mice increases fat utilization and energy expenditure, and reduces plasma TG, 
glucose, insulin, and hepatic TG [5,6,7].  
The liver secretes TAG as very-low density lipoprotein (VLDL) from a cytosolic 
TAG pool whose availability limits VLDL assembly and stability (Fig. 1.3.). In the TAG 
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synthetic pathway glycerol-3-phosphate acyltransferase (GPAT) catalyzes the rate-
limiting acylation of glycerol-3-phosphate (glycerol-3-P) with acyl-CoA generating 
lysophosphatidic acid (LPA). Subsequent reactions, catalyzed by LPA acyltransferase and 
diacylglycerol acyltransferase (DGAT), generate diacylglycerol and finally TAG. Newly 
synthesized TAG is either deposited in intracellular lipid vacuoles or exported in VLDL 
particles. Reduced hepatic TG administrated by FGF21 to obese rats and mice is 
accompanied by a decrease in lipogenic gene expression of GPAT1, DGAT2, ACC1, FAS, 
stearoyl-CoA desaturase-1, and fatty acid elongase-6, and stimulation of PPARα lipolytic 
target genes [6,7].  
Recombinant FGF21 (rFGF21) is currently being investigated as therapeutic 
against high blood lipids and type-2 diabetes [14]. However, the high costs of producing 
rFGF21 and the mode of delivery by injection are important limitations to its wide 
therapeutic use. A cost effective and practical alternative is to stimulate endogenous 
FGF21 production through diet.  
 
(R)--lipoic acid  
(R)-α-Lipoic acid (LA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic 
acid, is a naturally occurring dithiol compound found in green-leafy vegetables and red 
meats. LA is synthesized enzymatically from octanoic acid in most prokaryotic and 
eukaryotic microorganisms as well as plant and animal mitochondria [15]. It contains one 
chiral center and has both R- and S-enantiomeric forms (Fig. 1.4.). Beside synthesized, 
LA is also absorbed from dietary sources such as muscle meats, heart, kidney, and liver, 
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and to a lesser degree, fruits and vegetables [16]. However, the amounts of LA consumed 
in the traditional Western diet is not appreciable; therefore, dietary supplements are the 
primary sources of LA (typically ranging from 50 to 600 mg), and most positive health 
outcomes reported in the literature derived from LA supplements. 
Growing evidences show that orally supplied LA elicits biochemical activities 
with potential therapeutic value against a host of pathophysiological conditions, including 
diabetic polyneuropathies, age-associated cardiovascular, cognitive, and neuromuscular 
deficits [15]. LA has been described as a potent biological antioxidant and a 
detoxification agent (Fig. 1.5.). Many cases indicate that LA was not directly exerting its 
anti-oxidation abilities but by modulating glutathione (GSH) via nuclear factor 
(erythroid-derived 2)-like 2 (transcription factor Nrf2), and then plays an important role 
for protection against ischemic damage [17]. Besides, LA/DHLA has also been reported 
to improve age-associated cardiovascular, cognitive, and neuromuscular deficits, and has 
been implicated as a modulator of various inflammatory signaling pathways [18-23]. This 
impressive array of cellular and molecular functions has piqued considerable interest 
among the lay public and the research community for the use of LA both as a nutritive 
supplement and as a pharmacotherapy.  
Studies done by Diesel et al. showed that LA/DHLA mediates insulin pathway 
and glucose uptake by modulating the IR/PI3K/Akt pathway at different levels (Fig. 1.6.). 
The mediation of LA with the insulin-signaling cascade via different levels of regulatory 
components proved beneficial in animal studies due to the improvements made in skeletal 
muscle glucose uptake, whole-body glucose tolerance, and insulin resistance [26,27]. 
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Beyond that, improvements in glucose handling were also detected in clinical trials both 
intravenously and orally with type 2 diabetics taking LA [27-29]. 
Recently, the TG-lowering properties of dietary LA have been recognized, first in 
laboratory animals [30,31] then in clinical trials [32,33]. Despite these reports, the 
mechanism by which LA regulates blood TG is not well known and the degree to which 
LA can improve severe hypertriglyceridemia poorly documented.  
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Table 1.1. Therapies for managing dyslipidemia 
Therapy TG LDL-C HDL-C Possible side effects 
Fibrates  40-60%  5-30%  15-25% 
Myopathy, rhabdomyolysis, 
elevated liver enzymes 
Statins  20-40%  18-55%  5-15% 
Myopathy, rhabdomyolysis, 
elevated liver enzymes 
Niacin  30-50%  5-25%  20-30% 
Flushing, worsening glycemia, 
elevated liver enzymes 
Fish oil  30-50%  5-10%  5-10% 
Fishy aftertaste, gastrointestinal 
upset 
 
TG, triglyceride; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol 
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Figure 1.1. The mechanism of FGF21 receptor activation. (a). The FGFR/KLB 
receptor complex is silent without FGF21. (b). FGF21 binds to KLB via its C-terminus, 
then causes a conformational change in FGFR or FGF21 or both, which later allow 
FGF21 binds to FGFR via its N-terminus. The binding of FGF21 with FGFR/KLB 
receptor complex will trigger a following downstream signaling and a series of cellular 
responses. [Figure source: Kharitonenkov, Larsen et al. 2010]. 
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Figure 1.2. Effects of FGF21 on hepatocytes and adipocytes in animal models. a). 
FGF21 binds to FGFR/KLB receptor complex while β-Klotho stimulating glucose uptake 
in differentiated adipocytes through GLUT1 induction. b).  Fasting stimulates both 
FGF21 gene expression in hepatocytes and the circulating levels of FGF21 protein which 
can improve the lipolysis in adipocytes and ketogenesis and gluconeogenesis in liver 
directly induced by PPARα. [Figure modified from: P Iglesias, et al. 2012]. 
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Figure 1.3. Liver triglyceride (TAG) synthesis. ACC, acetyl-CoA carboxylase; ACS, 
Acyl-CoA synthase; AMPK, AMP-activated protein kinase; ATP:CL, ATP:citrate lyase; 
ChREBP, carbohydrate responsive element binding protein; DGAT, diacylglycerol O-
acyltransferase; FA:BP, fatty acid binding protein; FAS, fatty acid synthase; GK, 
glucokinase; G3PDH, glycerol-3-phosphate dehydrogenase; GPAT, glycerol-3-phosphate 
acyltransferase; HSL, hormone sensitive lipase; LXR, liver X receptor; PK, pyruvate 
kinase; PP2A, protein phosphatase 2A; PUFA, polyunsaturated fatty acid; SREBP-1c, 
sterol regulatory element binding protein-1c; VLDL, very low density lipoprotein; X5P, 
xylulose-5-phosphate.  
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Figure 1.4. LA and its reduced form, DHLA. DHLA is naturally generated in 
the body after the consumption of LA. The presence of an asymmetric carbon 
yields two enantiomers, R-LA (R-DHLA) and S-LA (S-DHLA), during organic 
synthesis. Only the naturally occurring R-LA (R-DHLA) enantiomer is bound 
covalently to the epsilon amino group of lysine residues of mitochondrial 
multienzyme complexes. 
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Figure 1.5. Proposed action of LA for induction of Phase II genes through Nrf2-
mediated transcription. LA may oxidize critical thiols on the Keap1 dimer to halt Nrf2 
degradation, and to prevent Keap1 from binding newly synthesized Nrf2. LA may also 
activate protein kinase signaling pathways that cause phosphorylation of Nrf2 on Ser40. 
This is the event that allows it to dissociate from Keap1 [24, 25]. Nrf2 can then localize 
to the nucleus and bind to the ARE, promoting transcription of genes for the Phase II 
detoxification response. [Figure source: K.P. Shay et al. et al. 2009]. 
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Figure 1.6. Role of lipoic acid in IR/PI3K/Akt-dependent activation of glucose 
uptake in skeletal muscle. Diesel et al. IR: insulin receptor. PTPB1: protein tyrosine 
phosphatase B1. IRS1: insulin receptor substrate 1. AMPK: AMP-activated protein 
kinase. PIP3: PtdIns-3, 4, 5-P3. PDK1: PtdIns-dependent kinase 1. Rab-GAP: GTPase-
activating protein. [Figure source: K.P. Shay et al. et al. 2009]. 
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CHAPTER 2 
 
REVERSAL OF OBESITY-INDUCED 
HYPERTRIGLYCERIDEMIA BY (R)-α-LIPOIC ACID 
 IN ZDF (fa/fa) RATS 
 
 
INTRODUCTION 
Controlling blood lipids is a major public health challenge of our time, when over 
1.4 billion adults worldwide are overweight or obese. Hypertriglyceridemia, defined as 
abnormally high fasting serum triacylglycerol (TG) levels (>150 mg/dl or >1.8 mM), is a 
major risk factor for coronary heart disease, liver disease, and type-2 diabetes that 
affects ～30% of U.S. adults [1,2]. Lowering blood TG translates into substantial 
cardiovascular benefits [3]. Conventional therapies for hypertriglyceridemia include 
dietary weight loss and exercise, dietary supplementation with fish oil or niacin, and drug 
intervention, which may include fibrates or combined therapy with statins when LDL-
cholesterol is elevated. Although some improvement is noted with drug therapies [4–7], 
serious associated side effects remain a concern [5, 8–10]. 
These impediments led us to examine the therapeutic potential of (R)--Lipoic acid 
(LA), a naturally occurring cofactor with lipid regulating properties. LA is synthesized 
enzymatically from octanoate in most prokaryotic and eukaryotic microorganisms as well 
as plant and animal mitochondria. Although de novo synthesis provides LA needed for its 
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function of cofactor in mitochondria, it can also be absorbed from foods (leafy green 
vegetables and red meats) and dietary supplements. There is strong evidence that orally 
supplied LA elicits biochemical activities with potential therapeutic value against an 
array of pathophysiological conditions, including diabetic polyneuropathies, age-
associated cardiovascular, cognitive, and neuromuscular deficits [11]. The TG-lowering 
properties of dietary LA have recently been recognized, first in laboratory animals [12–
15] then in human [16, 17]. 
Despite these reports, the mechanism by which LA regulates blood TG is not 
known and the degree to which LA can improve severe hypertriglyceridemia not well 
documented. We showed previously that LA supplementation prevented the rapid rise in 
blood plasma VLDL-TG that occurs between week 7 and week 9 of age in ZDF rats [14]. 
In the present study, we sought to determine the extent to which short-term dietary 
supplementation with LA affects overt hypertriglyceridemia, and to identify the 
molecular targets of LA. Results show that feeding LA to ZDF rats reversed 
hypertriglyceridemia, lowered abdominal fat mass, repressed genes of long-chain fatty 
acid and glycerolipid synthesis in the liver and adipose tissue, upregulated the production 
of fibroblast growth factor 21 (FGF21), and upregulated specific PPARα target genes 
involved in long- and medium-chain fatty acyl ester metabolism. 
 
MATERIALS AND METHODS 
Animals and diets 
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Obese male Zucker rats (ZDF/GmiCrl-fa/fa, 7-week old) were purchased from 
Charles River Laboratories and handled throughout in accordance with Institutional 
Animal Care and Use Committee approved guidelines. The feeding study was designed 
as an intervention trial where LA (3 g/kg diet, MAK Wood) is administered in the diet 
after blood TG has become elevated. At this level of supplementation we estimate LA 
intake to approximate 200 mg/kg body weight per day. Upon arrival, rats were acclimated 
for two weeks in individual cages in a controlled environment (ambient temperature 22 ± 
2 C, 12:12-h light–dark cycle) with free access to food (Purina 5008, 26.8% calories from 
protein, 16.7% from fat, 56.4% from carbohydrates) and water. At 9 weeks of age, the 
rats were randomly assigned to one of two treatments (Purina 5008 + LA or Purina 5008 
pair-feeding) for two weeks. Throughout the trial, animals were given two-day feeding 
rations between 1 and 3 pm and provided MilliQ water to drink. Food and water intake as 
well as body weight were recorded every other day. 
 
Blood plasma analyses 
Three-hour fasted blood was collected at the beginning and end of the trial in 
EDTA-coated tubes and plasma obtained by centrifugation at 12,000×g for 1 min and 
stored at －80 °C. Plasma TG was measured using the Serum Triglyceride Determination 
kit (Sigma–Aldrich). NEFA and ketone bodies (3-β-hydroxybutyrate + acetoacetate) were 
determined enzymatically by using commercial kits (Wako Diagnostics). Insulin and 
FGF21 were measured by ELISA (Millipore). 
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Tissue sampling 
At 11 weeks of age, rats were anesthetized with inhalant isoflurane and pancreas, 
liver, abdominal fat (epididymal + mesenteric + omental + retroperitoneal fat), small 
intestine, and skeletal muscle (soleus and gastrocnemius) were quickly removed, 
weighed, frozen in liquid N2, and stored at –80 °C. 
 
Quantitative Real-Time PCR (qRT-PCR) 
Total RNA was isolation from tissue using TRIzol and treated with DNase I. RNA 
integrity was confirmed on an Agilent Bioanalyzer 2100. First strand cDNA was 
synthesized with oligo(dT) and random primers using BioRad iScript. qRT-PCR was 
performed on a BioRad CFX96 using SYBR Green supermix. Amplicon authenticity was 
confirmed by melt curve analysis and agarose gel electrophoresis. PCR efficiencies were 
assessed with serial dilutions of the template (0.001–100 ng cDNA/reaction) and 0.3 lM 
of each primer, and plotting quantification cycle (Cq) vs. log amount of template. PCR 
efficiencies between target genes and housekeeping genes were comparable, thus 
unknown amounts of target in the sample were determined relative to cyclophilin A 
(Ppia) and 60 S acidic ribosomal protein P0 (Rplp0). Primer sequences are shown in 
Table 2.1. 
 
Western blotting 
Liver, skeletal muscle and adipose tissues were homogenized as previously 
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described [14]. Commercial antibodies to FASN (BD Biosciences), ACC, phospho-ACC 
(Ser 79), AMPK (clone 23A3), and phospho-AMPK (Thr 172, clone 40H9) from Cell 
Signaling, α-tubulin (clone 6–11B-1, Sigma–Aldrich), and β-actin (clone AC-15, Sigma–
Aldrich) were used. Antibody binding was visualized using LiCOR IR Dye secondary 
antibodies and Odyssey scanner. 
 
Immunohistochemistry 
Immunohistochemistry experiments were carried out to determine which endocrine 
cells of the pancreas produce FGF21. To that end, anti-FGF21 (LifeSpan Biosciences, 
LS-B5864), anti-glucagon (a-cells, Dako, A0565), and anti-pre/proinsulin (β-cells, Dako, 
A0564) antibodies and formalin-fixed, paraffin-embedded pancreas specimens of ZDF rat 
were used. Antibody to FGF21 was detected with anti-rabbit secondary (Vector, BA-
1000) and alkaline phosphatase staining kits (Vector AK-5000; Vector SK-5100), which 
produced a fuchsia- or red-colored deposit. Antibody to glucagon and antibody to insulin 
were stained using a horseradish peroxidase-based detection system (Dako LSAB+, 
K0690) and 3,30-diaminobenzidine chromogen substrate (Dako DAB+, K3468), which 
produced a brown precipitate. Tissues were also stained with a positive control antibody 
(Factor VIII) to ensure that the tissue antigens were preserved and accessible for analysis. 
The negative control consisted of performing the entire immunohistochemistry procedure 
on adjacent sections in the absence of primary antibody. Slides were imaged with a DVC 
1310C digital camera coupled to a Nikon microscope. 
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Statistical analysis 
Statistical significance was determined by unpaired two-tailed Student t-test with 
Welch’s correction. All statistical tests were performed to the 5% significance level. 
 
RESULTS AND DISCUSSION  
The present study demonstrates that dietary supplementation with LA for two weeks 
ameliorates whole-body lipid status in ZDF rats, a model of obesity and severe 
hypertriglyceridemia. Using this model we showed previously that LA supplementation 
prevented the rapid rise in blood plasma VLDL-TG that predictably occurs between 7 and 
9 weeks of age [14]. In the present study, LA not only stopped the progression of 
hypertriglyceridemia, but also normalized blood TG (Fig. 2.1). This situation is relevant 
to the human situation where individuals seek treatment after hypertriglyceridemia is 
diagnosed. 
Initial and final body weights did not differ between treatments nor did weight gain, 
food intake, and liver weight at the end of the trial (Table 2.2). LA lowered abdominal fat 
mass (–2.4 g/rat, P < 0.05) and abdominal adiposomatic index (–0.5%, P < 0.05) (Table 
2.2). At the end of the trial, all ZDF rats regardless of treatment were hyperinsulinemic 
(10–12 ng insulin/ml). Dietary LA did not alter blood plasma NEFA concentrations, 
which rose from 0.8 mM to 1.1 mM, suggesting active lipolysis in the adipose tissue 
prevailed. It also suggests that the uptake by peripheral tissues of NEFA released from fat 
deposits was not stimulated by LA. Plasma ketone bodies were not significantly different 
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among treatment groups at the end of the trial (Pair-fed, 116 ± 18 lM; LA, 90 ± 10 lM). 
As ketone bodies rise in the blood during fasting when glucose is not readily available, 
the present data indicate that LA did not stimulate ketogenesis and both groups of animals 
displayed comparable degree of fasting. 
Since the diet used in the study is low in fat and high in carbohydrates, lipogenesis 
from carbohydrates in the setting of overnutrition is stimulated in ZDF rats. Hence, the 
changes observed in lipid status are explained primarily by postprandial changes to the 
conversion rate of carbohydrates to fat. To ascertain the molecular targets of LA, gene 
expression of enzymes involved in de novo fatty acid and TG syntheses was determined 
(Fig. 2.2). In liver, feeding LA significantly repressed expression of Acly (–60%), Acaca 
(–61%), Fasn (–50%), Gpam (–52%), Dgat2 (–46%), and Pnpla3 (–92%). Similarly, in 
epididymal fat pad, mRNA levels of Acly (–38%), Acaca (–54%), Fasn (–57%), Gpam (–
44%), and Pnpla3 (–64%) were repressed or trended down in LA-fed animals. Decreases 
in liver Acaca and Fasn expression translated into significant changes in protein levels of 
ACC (–48%, P < 0.007) and FASN (–80%, P < 0.0002) (Fig. 2.3A). FASN abundance 
was decreased by LA (although not significantly) in epididymal fat and gastrocnemius 
muscle (Fig. 2.3B,C). The downregulation of Acly, Acaca, and Fasn in the liver and 
adipose tissue of LA-fed animals is an illustration of repressed carbohydrate-to-fat 
conversion. Operating simultaneously to lower blood TG, we showed that LA enhances 
the clearance of TG-rich chylomicron-like particles [14]. The role of the liver vs. non-
hepatic tissues in TG clearance is consequential as approximately one third of dietary 
fatty acids absorbed by the small intestine and assembled in chylomicrons is taken up by 
the liver [18] 
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In addition to regulating fatty acid de novo synthesis and esterification to 
glycerolipids, our data indicate that LA upregulated the gene expression of liver Acsm3, 
Cpt1b, and Acot1 (Fig. 2.2). Through these enzymes, LA has the potential to modulate 
cellular concentrations of medium- and long-chain fatty acids and their acyl-CoA 
metabolites. ACSM3 catalyzes the formation of medium-chain fatty acyl-CoA (C4 to C11 
in chain length) in mitochondria. This reaction serves two important functions that 
oppose steatosis, (i) the bioactivation of medium-chain fatty acids into intermediates of β-
oxidation, (ii) the production of hexanoyl-CoA and octanoyl-CoA, which repress the 
transcription of lipogenic genes Acaca and Fasn [19,20]. ACOT1 is a cytosolic enzyme 
that hydrolyzes long chain acyl-CoA (C12 to C20 in chain length) to the free fatty acid 
and CoA. Liver Acot1 expression was markedly stimulated upon treatment with PPAR 
agonist Wy-14643 [21], suggesting ACOT1 participates in lipid disposal. Free fatty acids 
generated in the cytosol by ACOT1 associate with fatty acid binding proteins (FABPs) 
and translocate to the nucleus where they are ligands of nuclear receptors, PPARs and 
HNF4 among others [22]. Thus, by converting acyl-CoA to free fatty acids, ACOT1 
may influence gene transcription. Although dietary LA induced liver Cpt1b expression, 
the absence of Cpt1a induction strongly suggests that the flux of long-chain fatty acyl-
CoA through mitochondrial β-oxidation was not stimulated by LA. One explanation may 
be that β-oxidation is already elevated in ZDF rats [23] thus further enhancement cannot 
be achieved. Exacerbation of mitochondrial β-oxidation to maximum capacity is 
perceived as detrimental in the obese and diabetic as incompletely oxidized fatty acids 
that are being generated contribute to insulin resistance [24]. In contrast, approaches to 
relieve mitochondria, such as through the depletion of malonyl-CoA decarboxylase (an 
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enzyme that promotes β-oxidation by relieving malonyl-CoA-mediated inhibition of 
CPT1a) have been shown to restore insulin sensitivity [25]. 
AMPK did not participate in LA’s TG lowering. Although AMPK was reportedly 
activated by LA in rodent tissues [26,27] and linked to the decrease in blood and muscle 
TG, LA feeding to ZDF rats decreased liver AMPK content (–62%, P < 0.0002) and 
failed to alter AMPK phosphorylation (Fig. 2.3). AMPK activity, assessed by the 
phosphorylation state of downstream target ACC (Ser79), did not change with LA. 
Timmers et al. reported that LA supplementation could prevent lipid accumulation 
associated with feeding a high-fat diet in Wistar rats independently of AMPK [28]. 
Disparity between studies is also attributed to the choice of animal model. AMPK activity 
is diminished in liver and muscle of ZDF rats [29], due in part to the absence of leptin-
dependent stimulation of AMPK [30,31]. Since feeding LA to leptin-resistant ZDF rats 
mimicked some of the metabolic consequences of AMPK (i.e. Downregulation of fatty 
acid esterification to form TG), an alternative mechanism independent of AMPK exists in 
ZDF rats. 
   The hormone-like protein FGF21 modulates lipid and glucose metabolism with 
potential therapeutic benefit for obesity-related metabolic disorders [32–35]. We report 
that LA, a naturally occurring micronutrient incorporated to the diet at a concentration 
comparable to LA intake considered safe in humans [11,36,37], upregulates FGF21 
production. Blood plasma FGF21 increased 330% in LA-fed rats vs. pair-fed controls (P 
< 0.0002, Fig. 2.4A). This observation coincided with the upregulation of liver Fgf21 
expression (+174%, P < 0.03, Fig. 2.4B). When compared to the liver, Fgf21 expression 
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was 2 to 5-fold lower in epididymal fat, and ～50-fold lower in distal ileum and soleus 
muscle. We did not observe inducement of Fgf21 by LA in adipose, distal ileum, or 
soleus, suggesting tissue specificity that may stem from LA hepatic metabolism. The 
quality of pancreatic RNA did not permit quantification of Fgf21 mRNA in this organ. 
However, FGF21 was detected immunologically in the endocrine pancreas of ZDF rats. 
Double labeling with pre/proinsulin and glucagon resulted in co-localized staining within 
insulin-producing β-cells (Fig. 2.4C). Weaker co-localized staining was focally present 
with FGF21 in glucagon-positive α-cells, but individual cells also showed single 
monochromatic staining for FGF21 or glucagon. The most intensely stained FGF21-
positive cells did not show significant co-localized staining with glucagon. Mechanism of 
LA-induced FGF21 expression is not yet known. Li et al. showed that sodium butyrate 
administered intraperitoneally to mice (500 mg/kg body weight) augmented Fgf21 
expression and circulating levels in a PPARα-dependent manner [38]. Induction of liver 
Fgf21 expression is required for normal activation of lipid oxidation and TG catabolism 
[32,39]. Conversely, genetic deletion of Fgf21 results in hepatosteatosis and 
hypertriglyceridemia [39]. The administration of recombinant FGF21 to obese rats and 
mice increases fat utilization and energy expenditure, and reduces plasma TG, glucose, 
insulin, and hepatic TG [32–34]. Reduced hepatic TG is accompanied by a decrease in 
lipogenic gene expression of Acaca, Fasn, Gpam, Dgat2, stearoyl-CoA desaturase-1, and 
fatty acid elongase-6, and stimulation of PPARα target genes [33,34]. Strikingly, feeding 
LA to lean and obese rats replicates these metabolic effects [14,40]. 
Taken together, our findings suggest that LA increases pathways of fatty acid 
oxidation while conjointly decreasing pathways of de novo production as a two-sided 
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complementary mechanism for how LA feeding decreases TG burden. The study shows 
that LA upregulates FGF21 production in the obese by inducing hepatic Fgf21 
expression. FGF21 expression in liver and serum may mediate the beneficial phenotype 
evoked by LA. 
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Table 2.1.  qRT-PCR primers used to quantify gene expression 
Gene Sequence (5’3’) a 
Product  
size (bp) 
GenBank b 
Acly ATGCCCCAAGATTCAGTCCC 160 NM_016987.2 
 CCACTGAAGGCTCATCTCGG   
Acaca GTTACTCGTTTTGGGGGAAA 298 NM_022193 
 CAGCCCACACTGCCTGTA   
Fasn GTGGAAGACACTGGCTCGAA 195 NM_017332.1 
 TGGTACACTTTCCCGCTCAC   
Gpam CGTGGGAAGGTGTTGCTATT 248 NM_017274 
 CAGCAATTGCCTCTTGGACT   
Dgat2 AACACGCCCAAGAAAGGTG 303 NM_001012345 
 AGGGCAGATGCCTCCAGAC   
Pnpla3 GTCGGATGAGAGCATCTGG 113 XR_085887.2 
 TAATGGGCAGGAGGTTGCAG   
Pparg GACACAGACAAAACATCAGTGG 156 NM_013124.3 
 CTGTGTCAACCATGGTAATTTCTTG   
Acsm3 CCAGCTGTGGGAAGCAGTAT 180 NM_033231.1 
 ACTCCAGATGGATTTGGTGGTT   
Cpt1a CCACAAATTACGTGAGTGACTGGTGG 213 NM_031559 
 CCAGAAGACGAATGGGTTTGAGTTCC   
Cpt1b GCTCATTTCCGGGACAAAGGCAAG 163 NM_013200 
 TTGGAGGTCTTGTTCCTTATGGGAC   
Acot1 GGCCACCCTGAGGTAAAAGGA 194 NM_031315.1 
 TGGTTTCTCAGGATAGTCACAGG   
Acox1 CAGCCCTACTGTGACTTCCA 279 NM_017340.2 
 ACCTGGGCGTATTTCATCAG   
Fgf21 CCTGGAGCTCAAAGCCTTGA 129 NM_130752.1 
 AAACTGCAGGCCTCAGGATC   
Ppia CGAGCTGTTTGCAGACAAAG 140 NM_017101.1 
 GTGTGAAGTCACCACCCTGG   
Rplp0 CTAGAGGGTGTCCGCAATGT 161 NM_022402 
 AGGAAGGCCTTGACCTTTTC   
a Shown as sense primer followed by antisense primer. 
b GenBank accession number.  
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Table 2.2. Body weight, weight gain, food intake, adipose and liver weights in ZDF 
rats at the end of the 2-week feeding trial 
 
Weight gain (% of initial body weight) = [(final body weight – initial body weight)/ 
initial body weight]×100. IAA, abdominal adiposomatic index; IH, hepatosomatic index. 
Data are shown as the mean ± SE of 8 rats/group. *P < 0.05 compared with the pair-fed 
group. 
 
  
33 
 
 
 
Figure 2.1. Time-courses of blood plasma TG (*P<0.001), insulin, non-esterified 
fatty acids (NEFA), and ketone bodies (3-β-hydroxybutyrate + acetoacetate) in 3-h 
fasted ZDF rats fed ± LA (n = 8). 
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Figure 2.2. Transcriptional changes induced by LA. mRNA levels (expressed as % of 
control pair-fed group, n = 8) of selected genes in liver, epididymal fat, and soleus 
muscle. *P < 0.05,**P < 0.02. PF, pair-fed group. 
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Figure 2.3. Lipoic acid represses FASN and ACC independently of AMPK. 
Immunoblots and densitometry depicting the tissue contents of phosphorylated AMPKα 
(pAMPKα, Thr 172), total AMPKα (sum of AMPKα1 and AMPKα2), phosphorylated 
ACC (pACC, Ser 79), total ACC (ACC1/2), FASN, and β-actin or α-tubulin as loading 
control. *Denotes statistical significance (n = 8); liver AMPKα, P < 0.0002; liver ACC, P 
< 0.007; liver FASN, P < 0.0002. PF, pair-fed group.   
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Figure 2.4. Lipoic acid induces FGF21 production. (A) Temporal changes in blood 
plasma FGF21 showing a 330% increase in LA-fed animals at the end of the trial (P < 
0.0002, n = 8). (B) Relative Fgf21 mRNA levels in 125 ng total RNA of each tissue, and 
normalized to housekeeping gene Ppia. Data represent the mean + SEM for 8 rats/group 
for liver (*P < 0.03), adipose, and soleus muscle; 4 rats/group for ileum. (C) 
Immunochemical detection of FGF21 in pancreatic islets showing strong co-localization 
within insulinpositive β-cells. Data is representative of two rats fed LA. 
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CHAPTER 3 
 
ELUCIDATE THE MECHANISM BY WHICH (R)-α-LIPOIC 
ACID UP-REGULATES FGF21 GENE EXPRESSION 
 
 
INTRODUCTION 
In Chapter 2, we report that naturally occurring dietary compound (R)--lipoic acid 
(LA) stimulates liver Fgf21 expression (+174%) and blood FGF21 levels (+330%) and 
replicates the adaptive metabolic response to fasting supported by FGF21 in vivo.  In 
particular, LA reversed hypertriglyceridemia, lowered abdominal fat mass, repressed 
genes of long-chain fatty acid and glycerolipid synthesis in the liver and adipose tissue, 
and upregulated specific PPAR target genes involved in long- and medium-chain fatty 
acyl ester metabolism [1]. The potential impact of this work is that LA may prove to be a 
safe and affordable means to stimulate FGF21 production. 
Based on this research, we hypothesize that FGF21 mediates the lipid lowering 
properties of LA (Fig. 3.1). Through this original work, we seek to shift current clinical 
practice by building a case for LA as a dietary inducer of endogenous FGF21 and a non-
prescription means to treat FGF21-responsive metabolic disorders. Elucidating the novel 
mechanism by which LA lowers TG will stimulate interest in its therapeutic use and 
justify further research on potential additive or synergistic effects of combined therapy 
with LA in lipid metabolic disorder. 
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We now seek to determine the precise mechanism of induction of the FGF21 
promoter by this dietary molecule. It means to identify the regions of the promoter that 
respond to LA and DHLA [2]. Since FGF21 may be regulated via an alternative distal 
promoter P1 (retrieved from the Transcriptional Regulatory Element Database, TRED), 
proximal promoter P2 may not account for full FGF21 inducibility and justifies the 
survey of a ~5,000-bp genomic DNA region that includes FGF21 distal promoter and 
spans clusters of acetylated histones and DNase hypersensitivity sites (Fig. 3.6). To this 
end, we have developed the FAIRE (Formaldehyde-Assisted Isolation of Regulatory 
Elements) assay to isolate regulatory regions that overlap to a large degree with DNase I 
hypersensitivity regions and identify nucleosome-depleted regions of chromatin by qPCR 
[3,4,5]. 
With this molecular tool, we plan to interrogate human FGF21 promoter regulation 
from HepG2 hepatocellular carcinoma cells under fed and starved states and in the 
presence of LA and DHLA. Our results will provide new insights into how nutrient-
responsive transcription factor binding sites regulate FGF21. 
 
MATERIALS AND METHODS 
HepG2 cells 
HepG2 cells were cultured in DMEM (5.5 mM glucose) supplemented with 10% 
fetal bovine serum (FBS) and 0.25X antibiotics/antimycotics to 40-50% confluence and 
used thereafter for the experiments. We conducted two experiments. Experiment 1 
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evaluated the inducibility of FGF21 upon serum withdrawal as an attempt to replicate 
FGF21 induction seen in vivo during starvation. To that end, HepG2 cells were cultured 
in the absence or presence of FBS as described in Figure 3.2 (Experiment 1). HepG2 cells 
continued to proliferate and maintain their morphology in absence of FBS. Serum 
withdrawal also eliminated potential confounding factors brought about by constituents 
found in FBS (e.g. growth factors, cytokines) with which the compounds of interest 
(dietary dithiols) may have unintended interactions. In Experiment 2, HepG2 cells were 
grown in the presence of LA (50 µM), DHLA (50 µM), or DMSO control for up to 48 
hours in the absence of FBS, according to the protocol described in Figure 3.2. The final 
concentration of DMSO was 0.1%, a concentration that is widely accepted as being inert 
to cells, including HepG2 cells. 
 
Abundance of FGF21 mRNA by quantitative Real-Time PCR (qRT-PCR) 
HepG2 total RNA was extracted at the 0, 12, 24, 36 and 48-hour time points by 
using BioRad Aurum kit, DNase I treated and quantified by NanoDrop. RNA integrity 
was confirmed by using Agilent Bioanalyzer 2100. First strand cDNA was synthesized 
with oligo(dT) and random primers using BioRad iScript. qRT-PCR was performed by 
using a BioRad CFX96 and SYBR Green supermix according to the manufacturer’s 
instructions. FGF21 mRNA was normalized to housekeeping gene cyclophilin A (PPIA). 
Primer sequences are shown in Table 3.1. 
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FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements)-qPCR 
The FAIRE assay is used to isolate active regulatory DNA loci through the identification 
of nucleosome-depleted region (‘open chromatin’), which is less efficiently cross-linked 
to protein and will segregate to aqueous phase during phenol/chloroform extraction. The 
purified input control HepG2 DNA and FAIRE DNA will later be detected by qPCR. 
Input control DNA and FAIRE DNA are all produced from HepG2 cells according to the 
FAIRE method in Figure 3.3.  For our purpose, HepG2 DNA will be isolated at the 48-
hour time point in Experiment 1 and at the 36-hour time point in Experiment 2. Mapping 
the response of the FGF21 promoter (chromosome 19) requires the design and validation 
of a collection of primer pairs whose qPCR products cover the ~5,000-bp region of 
interest. To that end, 25 primers pairs specific for human FGF21 promoter (PPs, 
overlapping between two adjacent PPs) were designed and validated.  
 
Statistical analysis 
Statistical significance was determined with the unpaired two-tailed Student t-test 
with Welch’s correction (Experiment 1), or the Kruskal-Wallis test followed by Dunn’s 
multiple comparison test (Experiment 2). All statistical tests were performed to the 5% 
significance level. 
 
RESULTS AND DISCUSSION  
Effect of serum starvation on FGF21 transcription in HepG2 cells 
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Serum withdrawal induced a marked increase in FGF21 mRNA abundance (Fig. 
3.4). The induction was significant from 24 hours (+5,530% vs. 0 hour) to 48 hours 
(+12,460% vs. 0 hour) after serum removal. In contrast, the reintroduction of serum (10% 
FBS) at 24 hours reversed the induction and brought FGF21 mRNA levels back down to 
pre-experimental concentrations. Housekeeping gene, PPIA, was not markedly affected 
by serum manipulation and remained highly expressed at all time points. The absence of 
serum for 48 hours did not stop HepG2 cells from proliferating. Cell confluence was not 
noticeably different among +/- serum treatments. 
 
Effect of LA and DHLA on FGF21 transcription in serum starved HepG2 cells 
Both LA and DHLA induced FGF21 mRNA levels when compared to vehicle 
control (Fig. 3.5). DHLA-mediated induction (+900%, P<0.019) of FGF21 vs. DMSO 
control was stronger than that of LA (+670%, P<0.024) at 36 hours. FGF21 induction by 
the dithiols was not significant at 48 hours, suggesting the induction was transient. 
FGF21 mRNA levels in DMSO controls at 36 hours were markedly different than those 
at 48 hours. The reason for this change is not entirely clear, it may be linked to the 
transient effect of the dithiols. Housekeeping gene, PPIA, was not markedly affected by 
the treatment and remained highly expressed at all time points. 
 
Design and validation of FAIRE-qPCR primer pairs 
The sequences of the 25 primer pairs are shown in Table 3.2. The authenticity of the 
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qPCR products generated with primers was confirmed by melt curve analysis and agarose 
gel electrophoresis. qPCR efficiencies were assessed with 5-fold serial dilutions of 
HepG2 DNA and plotting quantification cycle (Cq) versus log amount of template. 
Efficiency curves (EC %) were between 89% and 114% (Fig. 3.7). The 25 qPCR 
products covered 4,573 bp of FGF21 promoter (Fig. 3.8) with some overlap. 
 
Taken together, our findings in HepG2 cells treated with LA and DHLA reproduced 
the induction of hepatic FGF21 gene expression seen in LA-fed animals. Our data 
indicating that DHLA induced FGF21 mRNA levels with higher potency than LA suggest 
that DHLA may the relevant form of -lipoic acid in this process. Experimental evidence 
supports this view. Indeed, studies have shown that cells and tissues enzymatically 
convert LA into DHLA, and the conversion to DHLA is critical to support biological 
effects [6]. Attempts to enrich cells or mitochondria with exogenous LA using a 
triphenylphosphonium-conjugated lipoyl derivative showed that although the lipoyl 
conjugate accumulated in cells and mitochondria, it was not protective against a range of 
stressors as a consequence of its poor enzymatic reduction to dihydrolipoyl conjugate 
caused by steric hindrance. LA was protective after reduction to DHLA, a reaction 
catalyzed by thioredoxin reductase and glutathione reductase in the cytosol, and 
dihydrolipoyl dehydrogenase in mitochondria.  
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Table 3.1. Primer sequences for determining FGF21 coding mRNA by qRT-PCR 
Human gene Primer Sequence (5’3’) a Tm b 
FGF21 
F1 GGGAGTCAAGACATCCAGGT 60.0°C 
R1 GGCTTCGGACTGGTAAACAT 60.0°C 
PPIA 
F1 TTCATCTGCACTGCCAAGAC 56.2°C to 60.7°C 
R1 TGTCCACAGTCAGCAATGGT 56.2°C to 60.7°C 
a Shown as sense primer followed by antisense primer. 
b Appropriate annealing temperature. 
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Table 3.2. Sequences of the 25 primer pairs designed for FAIRE-qPCR assay 
 
PPs Sequence (5’3’) a 
Product  
size (bp) 
qPCR protocol b 
PP1 GTGGCACATGTCTGTGGTCT 193 isothermic qPCR 
 CGAGATTCCTTCAGGAAAGGT   
PP2 ATAGCACCGCTGACTGCAC 216 isothermic qPCR 
 ACCTCTGTGGTGGATTTTGC   
PP3 CTTCCACCAGCCTGTTTCTC 244 TD PCR  
 GGACCCAGGAACAACTCCTT   
PP4 GAGGTGGCGGAGATTCCTA    162 isothermic qPCR 
 AAAAGCGGACTGTGGATCTG    
PP5 CAGATCCACAGTCCGCTTTT 230 TD PCR  
 CTCCACCTTCCAGCCATC   
PP6 GATGGCTGGAAGGTGGAG 280 TD PCR  
 TGGCACCGGAAGAGAGAG   
PP7 GGTGCCAGGGCTTAGAGTC 159 TD PCR  
 AGCCTGGCAAACAGGTTCT   
PP8 GGGATGGAGAACCTGTTTGC 207 TD PCR  
 GCAGTGCAGGTCTGGAAAGT   
PP9 CCTTTTGGGGAATTCTAGGG  203 isothermic qPCR 
 GCCTTGGACCAGAGAAAATG   
PP10 GCATTTTCTCTGGTCCAAGG 207 isothermic qPCR 
 GGTCTCTGCGTCTTGATGGT   
PP11 CTACCATCAAGACGCAGAGACC  218 isothermic qPCR 
 TGCAGAGAAGAAAACGCTGACA   
PP12 GCAGAAAGAGAAGGCAGCAT 286 TD PCR  
 ACACCTTCTCCTGCCTCAC   
PP13/14 TGAGGCAGGAGAATGGTGTG 238 TD PCR  
 AGTCATCCTGCTGTGCTGTG   
PP15 ACCATTGAAGCACAGCACAG 213 isothermic qPCR 
 TTCTGTCACACCGGCATAAG   
PP16 TCGTGGTCTGCTGAGTAACG   167 TD PCR  
 AACAACCGGTGGGTATAGGG    
46 
 
PP17 TATACCCACCGGTTGTTTCC 238 isothermic qPCR 
 AATGGGAGGGTCAGTCTGTG     
PP18 AATCCTTCCCCACAGACTGA 193 isothermic qPCR 
 GGGAGCCTGGACTCCTAAGT   
PP19 CCAGACCCTTCTGCTCACAC   230 TD PCR  
 AGGGAGCTTTGGTCTGGACT   
PP20 AGGAGTCCAGACCAAAGCTC 247 isothermic qPCR 
 ACCCAGAGGGAAGACAGGTT   
PP21 AGCCAACCTGTCTTCCCTCT 218 isothermic qPCR 
 CAACCTCATCTGTCCCTGCT   
PP22 ATGTCCAGGGTCTGAGCATC  232 isothermic qPCR 
 ATGCAGATCACGCAGAACAA    
PP23 TCTTGTTCTGCGTGATCTGC  228 isothermic qPCR 
 TGTAACCTGGGGTCCTTTCA   
PP24 ACCCCAGGTTACATCATCCA 177 isothermic qPCR 
 CAGCTGACAGAACACCCTTG   
PP25 TCTGTCAGCTGAGGATCCAG     203 isothermic qPCR 
 GCACAGAAACCCACAGTCCT    
PP26 GGACTGTGGGTTTCTGTGCT 165 isothermic qPCR 
 ATCCTCCCTGATCTCCAGGT      
a Shown as sense primer followed by antisense primer. 
b qPCR protocol employed  for the validation of primer pairs. TD qPCR, Touch-down 
qPCR. 
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Figure 3.1. Hypothesis that fibroblast growth factor-21 (FGF21) is the missing link 
in LA-mediated disposal of fat in target tissues. TF = transcription factor. 
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Experimental 1: Effect of serum starvation on FGF21 transcription in HepG2 cells 
 
Experiment 2: Effect of LA & DHLA on FGF21 transcription in serum-free HepG2 cells 
 
 
Figure 3.2. Experimental design of HepG2 cell studies 
  
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. FAIRE assay protocol. [Adapted from Simon et al. 2012]. 
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Figure 3.4. Time-course of FGF21 mRNA abundance as affected by the presence or 
absence of serum (Experiment 1). reFBS indicates that FBS (10% final concentration) 
was reintroduced at 24 hours. Serum withdrawal strongly induced FGF21 mRNA steady-
state levels at 24, 36 and 48 hours. The reintroduction of serum blocked FGF21 induction 
at the 36 hours (*P < 0.0007) and 48 hours (*P < 0.0001) time points (n=6). 
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Figure 3.5. Time-course of FGF21 mRNA abundance as affected by LA and DHLA 
(Experiment 2). DHLA (+900%, P<0.019, n=6) and to a lesser extent LA (+670%, 
P<0.024, n=6) significantly increased FGF21 mRNA levels at 36 hours vs. DMSO 
control. Data not sharing a common letter at a given time point are significantly different. 
Cells were grown in the absence of serum from the 0-hour time point. DMSO, LA (50 
µM) or DHLA (50 µM) were added at 24 hours.  
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Figure 3.6. Human FGF21 gene and promoter structure, and positioning of 
promoter P1 and P2, the ~5,000-bp region to survey, and acetylated histone marks 
found near active regulatory elements. 
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Figure 3. 7. The qPCR efficiency curves (EC %) of the 25 primer pairs. Horizontal 
axis: Log Starting Quantity; Vertical axis: Cq value.    
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Figure 3. 8. Sequence (4,573 bp) of the human FGF21 5’ UTR (chromosome 19). 
 
Starts @ 49,255,156 
Ends @ 49,259,728 
AGAGAGGCTGGAGGGTC = start of predicted promoter P1 
AGGTTGGCCCACGGCCA = start of predicted promoter P2 
CTGTCAGCTGAGGAT…GCCGCCGAAA = 385 bases of Exon 1 of human FGF21 
 
TGAGATCATGCCATTACACTCCAGCCTGGGCAACAAGAGTGAAACTCCGTCTC
CAAAAAAAAATAAATAAAATTAGCTTGGCATGGTGGCACATGTCTGTGGTCTC
AGCTACACCGGATGCTAAGGCGGGAGGATCCCCGGAGCTCACAATGAGCCGC
GATAGCACCGCTGACTGCACTCCAGCTTGCGCGACAGAGAGGGACCCTGTCTT
AAAAAAAAAAAAAAAAAAAAAAAAAGAAAGTGGTCCAGGTTCCTACACCTT
TCCTGAAGGAATCTCGAGTCTCCCCTCCTGTAAGTTCCGCTGATACTGGACTCT
TCCACCAGCCTGTTTCTCAGGAGTACCTGTCTGTGAGGCGCAAAATCCACCAC
AGAGGTGGTGATGGGAAACGATAGTTCAAGTAAAACAAGAGAGGCTGGAGG
GTCAGGAGCGGAAGGAGCATCTTGGTTCCTGGAGGAGTAATGGCTGGGGAGG
TGGCGGAGATTCCTAGGGCCTTAGGAAGACCTGGAGAAGAGGTTGGGGGTGC
ACCTCCTGGTTCTGAAGGAGTTGTTCCTGGGTCCCAGGAACAACTGAGTGGG
GCAGTCCCCACTTACCCGAGCTGCTTGCAGGTGGCAGATCCACAGTCCGCTTT
TCGTGGCCGGAGCGCACCCTCCGCAAAGGCAGGCCACATCCGGCCGCCCCTG
GAACGCCAGGCGTCCGGCTATCCGGCCCGGCAGCCCTCCCCTCCGCGCAGCCT
GTCCGGACTGGCAGCGAGGGCTTGGGGAGGAGAGGAAGGAGAGGGCGCGGC
CGGGAGTCTCGCAGCGTCCGCCCTCCCGGGCCGGGCGGATGGCTGGAAGGTG
GAGCCCCGCCCGTCACTTGGCGCCGAGCCCCAGCGCCAGGGGCTAAGGCGAT
GGCCCCTGGGCCCACCGCTCCCCAGATCGGGGATGCAGGGGACCGCGCCCTG
CCCCTCCGCCCCGTCATTGACCTGCGCGAAGGCTTCACCCAGGGCAGGCTACC
TGGCTTCTGAGCAGCCGCAGCATCATTGCGTGGACCAGGAGACGGAGCGCCC
AGTTGCAATGCTGGAGCCGGGAGGTCCAATCCGCCGCCCTCTCTCTTCCGGTG
CCAGGGCTTAGAGTCGGCCCCCGACACCTGGGTGCTTCGAGCCTGGCCACGC
CCCAGCGGCTGGGCAGGGCCCCCGCACCTGGTCCCGGCGAGTGGAGCGATCG
TCCGCCCTCTGCCGCGTCCTCCTGGGGGATGGAGAACCTGTTTGCCAGGCTGC
CGCCGGAGCGCGCGAGGGCCTCCAGCCTGCAGGTGCTCCCGCGCCCACCAGG
GTCTCCGATCTCCCACACCCCCCGCCTCACCGTCCACACTCAAATTCCAGAAT
CCCAGCCCCTAGTCACTCCTTTTGGGGAATTCTAGGGTCCCGTGCCAAACTGC
TACTTTCCAGACCTGCACTGCACGAAGGCAACCATTCCAAGGCTGGAGACCG
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GAGTGGAACAGGGTCTGTTTCCCACGCCGTCAGCGGGGGCCGTGGCTGCCGG
CGCCAGAGACAAAGGCCTCTGCCCGCTTGTCACCTAATTAAAGCATTTTCTCT
GGTCCAAGGCCCACCTCCAGCATCGCCAACCCCGAGCAGGGCAGGCTAACGT
AGGGTCCAGCCCTACGGGGCTTTGCGGGTGGGTGTTCTTCCCCTGTGAGGAG
AGGAGAGATTGTAAGAAATAAAGACACAAGACAAAGAGATAAAGAGAAAAC
AGCTGGGCCCGGGGGACCACTACCATCAAGACGCAGAGACCGGTAGTGGCCC
CGAATGGCTGGGCGCGCTGATATTTATTGTATACAAGACAAGGGGGGGCAGGA
TAAGGAGGGTGAGTCGTCCAAATGACTGATAAGGTCAAGCAAGTCACGTGAT
CATGGGACAGGGGGCCCTTCCCTTTTAGGCAGCCGAAGCAGAAAGAGAAGGC
AGCATATGTCAGCGTTTTCTTCTCTGCACTTATAAGAAAGATCAAAGACTTTAA
GACTTTCACTATTTCGGGCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACT
TTGGGAGGCTGAGGCGGGCGGATCACAAGGTCAGGAGGTGGAGGCCATCCTG
GCTAACACGGTGAAACCCTGTCTCTACTAAAAATACAAAAAATTATCCGGGCG
CGTGGTGGAGGGCGCCTGTAGTCCTAGCTATTTGGGAGGGTGAGGCAGGAGA
ATGGTGTGAACCCAGGAGGCGGAGATTGCAGTGAGCCGAGATCACGCCACTG
CACTCCAGCCTGGGGGACAGAGCGAGACTCCGCCTCAAAAAAAAAAAAAAA
AAGGCTTTCACTATTTCTTCTACCGCTATCTACTACGAACTTCAAAGAGGAACC
AGGAGTACGGGAGGAAAATGCAAGAGGACAAGGAGCGTGACCATTGAAGCA
CAGCACAGCAGGATGACTGCGGGCAGGCCTAGATAATACCCAGCCTCCCACA
AGAAGCTGGTGGAGCAGAGTGTTCCCTGACTCCTCCAAGAAAAGGAGATTCC
CTTTCGTGGTCTGCTGAGTAACGGGTGCCTTCCCAGACACTGGCGTTCCCGCT
TGACCAAGGAGCCCTCAAGAGGCCCTTATGCCGGTGTGACAGAAGGCTCACC
TCTTGCCTTCTAGGTCACTTCTCACAATGTCCCTTCAGTACCTGACCCTATACC
CACCGGTTGTTTCCTGGTTATATTAGTTATACAACAAAGAATAAAAGTAATAGCT
AATGATTAATAATGTTTACACTAATGATTGATACTGTCCATGATCATCTCTATATC
TAATTTGTATGATAACTATTCTTATTCTAACTATTTTCTTTATTATACTGAAACAGT
TTGTGCCTTCAGTCTCTTGCCTCGGCACCTGGGTAATCCTTCCCCACAGACTGA
CCCTCCCATTCAAGATACATCAATGTCAAAGACTCAGGAGTTTGACTTGATTCC
CAGAAGTTTAACCATCATCTCCCCAGGCTCGGGACTCCCAGCACCCAGACCCT
TCTGCTCACACCCAGCAGTCCAGGCCCCCAGACCCTCCTCCCTCAGACTTAGG
AGTCCAGGCTCCCGGCCCCTCCTTCCTCAGACCCAGGAGTCCAAGCCCCCTGC
CCCTCCTTCCTCAGACCCAGGAGTCCAGGACCCCAGCCCCTCCTTCCTCACAC
CCACGAGTCCAGATCCCTAGCCCCTACTCCCTCAGACCCAGGAGTCCAGACCA
AAGCTCCCTCCTCCCTCAGACCCAGGAGCCCAAGTTCCCCAGCCCCTCCTCCC
TCAGATCCAGGAGTACAGGCCCAGACCCTCCTCCCTCAGACCCAGGAGTCCA
GGCCCCCCACCCCTCCTCCCTCAGACCCAGGAGTCCAGAGCCCCAGCCCTCCT
CCCTCAGACACAGAAGGCCTACCCTTGCACCCTTAGGGGCTCCAGGAAATTAG
CCAACCTGTCTTCCCTCTGGGTGCCCACTCCAGGGCCTGGCTTGGCTGCCAAC
TCCAGTCAGGGACTTTCAGCCACCCCTCCCCCCAGGTTATTTCAGGAGCACCT
GCCTGGGCCTGGGATGGCTTCTCTGGTGAAAGAAACACCAGGATTGCATCAG
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GGAGGAGGAGGCTGGGATGTCCAGGGTCTGAGCATCTGAGCAGGGACAGATG
AGGTTGAGGTTGGCCCACGGCCAGGTGAGAGGCTTCCAAGGCAGGATACTTG
TGTCTCAGATGCGGTCGCTTCTTTCATACAGCAATTGCCGCCTTGCTGAGGATC
AAGGAACCTCAGTGTCAGATCACGCCCTCCCCCCAAACTTAGAAATTCAGATG
GGGCGCAGAAATTTCTCTTGTTCTGCGTGATCTGCATAGATGGTCCAAGAGGT
GGTTTTTCCAGGAGCCCAGCACCCCTCCTCCCTCCGACTCAGGTGCTTGAGAC
CCCAGATCCTTCTCTCTGAGACTCAGGAATGTGGGCCCCCAGCCCCTTTCACC
TGGGTCCCAGCTAACCCGATCCTCCCCTCCCTCATCCCCTAGACCCAGGAGTC
TGGCCCTCCATTGAAAGGACCCCAGGTTACATCATCCATTCAGGCTGCCCTTGC
CACGATGGAATTCTGTAGCTCCTGCCAAATGGGTCAAATATCATGGTTCAGGCG
CAGGGAGGGTGATTGGGCGGGCCTGTCTGGGTATAAATTCTGGAGCTTCTGCA
TCTATCCCAAAAAACAAGGGTGTTCTGTCAGCTGAGGATCCAGCCGAAAGAGG
AGCCAGGCACTCAGGCCACCTGAGTCTACTCACCTGGACAACTGGAATCTGGC
ACCAATTCTAAACCACTCAGCTTCTCCGAGCTCACACCCCGGAGATCACCTGAG
GACCCGAGCCATTGATGGACTCGGACGAGACCGGGTTCGAGCACTCAGGACTG
TGGGTTTCTGTGCTGGCTGGTCTTCTGCTGGGAGCCTGCCAGGCACACCCCAT
CCCTGACTCCAGTCCTCTCCTGCAATTCGGGGGCCAAGTCCGGCAGCGGTACC
TCTACACAGATGATGCCCAGCAGACAGAAGCCCACCTGGAGATCAGGGAGGAT
GGGACGGTGGGGGGCGCTGCTGACCAGAGCCCCGAAA 
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CHAPTER 4 
 
CONCLUSION 
 
 
Recent research work in metabolism and nutrition has shed new light on the ability 
of FGF21 to improve metabolic disorders related to glucose and lipid homeostasis and on 
the inducibility of the FGF21 gene by bioactive food compounds [1]. Research into the 
metabolic effects and molecular mechanism of action of -lipoic acid as a relevant 
natural inducer of FGF21 production has been pursued in this thesis. Our research shows 
that (R)--lipoic acid stimulated liver FGF21 gene expression (+175%) and blood FGF21 
levels (+330%) and replicated the adaptive metabolic response to fasting supported by 
FGF21 in vivo. Further studies of the regulation of the FGF21 promoter will have 
implications both in basic research and in clinical setting. 
In recent years, there has been a significant push toward the development of new 
therapeutics that target lipid risk factors other than hypercholesterolemia, such as 
hypertriglyceridemia. There is a growing interest in the therapeutic potential of -lipoic 
acid against dyslipidemia. Seven clinical trials on the topic were published over the 
previous three years out of a total of 17 clinical trials on -lipoic acid. Careful review of 
these studies indicates -lipoic acid (600 mg/day) safely lowers blood triacylglycerol 
once triacylglycerol have become elevated [2-8]. As of now, however, no clinical trial 
with -lipoic acid in hypertriglyceridemic subjects has been conducted in the United 
58 
 
States. Before clinical trials with -lipoic acid can be initiated, the molecular targets and 
cellular signaling of -lipoic acid will need to be uncovered. 
The molecular mechanism of -lipoic acid proposed herein supports a shift from 
the current paradigm that -lipoic acid acts as an antioxidant to the new concept that -
lipoic acid regulates gene transcription. Although historically recognized as an 
antioxidant able to reduce various oxidized targets (including other antioxidants), -
lipoic acid does not act as a traditional antioxidant here. At the doses ingested from a 
supplemented diet and because it is very rapidly metabolized, -lipoic acid does not 
accumulate to sufficient cellular levels (low M) to have a lasting impact similar to that 
of traditional antioxidants (e.g., ascorbate or tocopherol) [9, 10]. Rather, -lipoic acid 
transiently stimulates cell signaling and transcription pathways relevant to lipid 
homeostasis [11]. Experimental evidence collected in recent years, including our own, 
support a new yet definable mechanism of -lipoic acid action that ultimately results in 
its universal lipid-lowering effect. 
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